Table 1.

Demographics, tumor location, tumor type, molecular tumor profile and progression-free survival for all patients

ID	Gender, age	Tumor location	Tumor type	Molecular status	BBB break down	Recurrency/progressive disease (months)
1	M, 70	R parietal	GBM °IV	IDH1/2 WT, ATRX retention, MGMT non-methylated	Yes	21
2	F, 61	L parieto-temporal	GBM °IV	IDH1/2 WT, ATRX retention, MGMT non-methylated	No	3
3	F, 54	R temporal	Giant cell GBM °IV	IDH1/2 WT, ATRX retention, MGMT intermediate methylated	Yes
4	F, 46	R Temporo-insular	Diffuse astro-cytoma °II	IDH1 pos, 1p/19q no LoH, ATRX retention	No
5	F, 29	L frontal	Diffuse astro-cytoma °II	IDH1 pos, 1p/19q no LoH, ATRX loss	(Yes)
6	M, 70	R temporo-insular-frontal	Anaplastic astro-cytoma °III	IDH1/2 WT, ATRX retention, MGMT methylated	No	11
7	F, 63	L insular	GBM °IV	IDH1/2 WT, ATRX retention, MGMT non-methylated	Yes
8	F, 52	R occipital	GBM °IV	IDH1/2 WT, ATRX retention, MGMT non-methylated	Yes	15
9	F, 58	R parieto-insular	GBM °IV	IDH1/2 WT, ATRX retention, MGMT non-methylated	Yes	7
10	M, 69	L parietal	GBM °IV	IDH1/2 WT, ATRX retention, MGMT methylated	Yes	1
11	M, 43	L fronto-insular	LGG	N/A	(Yes)

BBB blood–brain barrier (= contrast enhancement), F female, GBM glioblastoma multiforme, IDH isocitrate dehydrogenase, L left, LGG low-grade glioma, LoH loss of heterozygosity, M male, MGMT O-6-methylguanine-DNA-methyltransferase, R right, WT wild type, (Yes) faint contrast enhancement